Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial

Ryan, Donna H.; Lingvay, Ildiko; Deanfield, John; Kahn, Steven E.; Barros, Eric; Burguera, Bartolomé; Colhoun, Helen M.; Cercato, Cíntia; Dicker, Dror; Horn, Deborah B.; Hovingh, G. Kees; Jeppesen, Ole Kleist; Kokkinos, Alexander; Lincoff, A. Michael; Meyhöfer, Sebastian M.; Oral, Tuğçe Kalaycı; Plutzky, Jorge; Beek, André P. van; Wilding, John; Kushner, Robert F.

doi:10.1038/s41591-024-02996-7

articleNature MedicineMay 13, 2024HYBRID OA

Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial

DHDonna H. Ryan ILIldiko Lingvay JDJohn Deanfield SESteven E. Kahn EBEric Barros

Pennington Biomedical Research Center · The University of Texas Southwestern Medical Center · +19 more institutions

PubMed

Indexed incrossrefpubmed

Abstract

Abstract In the SELECT cardiovascular outcomes trial, semaglutide showed a 20% reduction in major adverse cardiovascular events in 17,604 adults with preexisting cardiovascular disease, overweight or obesity, without diabetes. Here in this prespecified analysis, we examined effects of semaglutide on weight and anthropometric outcomes, safety and tolerability by baseline body mass index (BMI). In patients treated with semaglutide, weight loss continued over 65 weeks and was sustained for up to 4 years. At 208 weeks, semaglutide was associated with mean reduction in weight (−10.2%), waist circumference (−7.7 cm) and waist-to-height ratio (−6.9%) versus placebo (−1.5%, −1.3 cm and −1.0%, respectively; P <…

Citation impact

274

total citations

FWCI: 85.25
Percentile: 100%
References: 25

Citations per year

Authors

20

Topics & keywords

Topics

Keywords

Semaglutide
Medicine
Placebo
Weight loss
Waist
Adverse effect
Overweight
Internal medicine

UN Sustainable Development Goals

Good health and well-being

No related works found for this paper.